French drugmaker Sanofi (Euronext: SAN) has announced positive data from the Phase III IKEMA trial of Sarclisa (isatuximab) in multiple myeloma.
The trial, which is testing the monoclonal antibody with chemotherapy as an option for people with relapsed multiple myeloma, met the primary endpoint at its first planned interim analysis.
The therapy produced significantly prolonged progression-free survival, compared to standard of care carfilzomib and dexamethasone alone, and no new safety signals were identified.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze